Introduction
Dupuytren's disease (DD) is a debilitating condition of the hand [1, 2] characterized by the formation of collagenous cords in the palmar and/or digital fascia and permanent finger contractures. Despite being amongst the most common inherited connective tissue diseases [1] [2] [3] [4] , the etiopathology of DD has remained elusive since its description in the 1830s [5] . While microsurgical excision [6] of the contractile cord tissue can temporarily restore dexterity, this and other treatment approaches fail to prevent disease recurrence in more than 30% of patients [7] [8] [9] [10] . There is a clear need for a better understanding of the molecular pathology of DD to achieve more effective therapeutic approaches.
Due to the unique physiology of the palmar fascia and the lack of understanding of DD at a molecular level, there are no established animal or immortalized cell models in which to study DD development. We take the approach of comparing primary fibroblasts derived from surgically resected DD contracture (cord) tissue (DD cells) to fibroblasts derived from the palmar fascia of the adjacent, phenotypically unaffected digit exposed during surgery (PF cells). While DD may be associated with increased cancer mortality in some populations [11, 12] , patients with a family history of finger contractures do not display any major chromosomal rearrangements or deletions [13] and DD is considered a benign, heritable fibrosis [4] . Single nucleotide polymorphisms (SNPs) have been identified as potential markers of this heritability [14] , and these polymorphisms are predicted to be present in all somatic tissues in these patients rather than limited to diseased tissues. PF cells can therefore be viewed as genetically matched "latent disease" cells that carry the same predisposing SNPs as DD cells, making them
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
the ideal controls for studies of the molecular mechanisms that promote disease development in this population. In addition, we derive a second control group of palmar fascia fibroblasts (CT cells) from patients with no history of DD who are undergoing surgeries for unrelated reasons, such as carpal tunnel release. We consider CT cells to be normal controls and useful comparators to patient matched PF/DD cells in studies designed to identify characteristics that are specific to cells predisposed to DD development [15, 16] .
Using these unique cell models, we have focused on identifying molecules that regulate the proliferation and differentiation of palmar fascia fibroblasts into myofibroblasts, the hyper-contractile cell type that remodels the palmar fascia to induce finger contractures in DD. Several research groups have previously reported gene expression analyses of DD tissues or cells with the aim of identifying dysregulated genes with potential roles in myofibroblast development [13, [16] [17] [18] [19] [20] . Our previous studies have focused on TGFB1, encoding transforming growth factor-1 (TGF-1) and TGF--induced genes such as periostin [21] . In parallel, we and others [19] have identified IGFBP6 as a significantly down regulated transcript in DD tissue. The relevance of downregulated IGFBP6 expression to the proliferation and differentiation of palmar fascia fibroblasts into DD myofibroblasts has not been previously explored.
IGFBP6 encodes insulin-like growth factor binding protein (IGFBP)-6, one of a family of six secreted proteins that bind insulin-like growth factors (IGFs) -I and -II with high affinity and regulate their bio-availability [22] . While most IGFBPs can regulate the availability of both IGF-I and IGF-II under normal physiological conditions, IGFBP-6 is A C C E P T E D M A N U S C R I P T
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unique in displaying a 50 fold higher affinity for IGF-II [23, 24] , identifying it as an IGF-II-specific binding protein under normal physiological conditions [23] .
In this study, we demonstrate that IGFBP6 mRNA and IGFBP-6 protein levels are down-regulated components of DD cells, and that IGF2 mRNA and IGF-II peptide levels are up-regulated in DD cells relative to controls. Recombinant IGFBP-6 was found to inhibit the proliferation of DD, PF and CT cells, and co-treatment with IGF-II was mostly ineffective at neutralizing these effects. IGF-II significantly enhanced DD cell contractility and this effect could be abrogated by IGFBP-6. Overall, these findings implicate IGFBP-6 and IGF-II as previously unrecognized regulators of DD cell proliferation and contractility that may have potential as therapeutic targets in this and related fibro-contractile diseases.
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Immunohistochemistry
Surgically resected DD cord and patient matched, phenotypically normal palmar fascia samples were fixed in 10% formalin prior to dehydration, paraffin embedding and microtome sectioning. Paraffin-embedded specimens were sectioned (5 m), dewaxed, rehydrated and treated with a 3% hydrogen peroxide solution to quench endogenous peroxidase activity. Slides were treated with serum-free blocking reagent (Background Sniper, Biocare Medical, Concord, CA) for 10 min and rinsed in PBS prior to incubation with rabbit polyclonal IGFBP-6 (Austral Biologicals, San Ramon, CA) overnight at 4C.
After a wash in PBS, the slides were incubated (30 min, 22C) with a biotinylated secondary anti-rabbit antibody (Vector labs, Burlington ON), washed briefly in PBS, and 
the RPLP0 endogenous control (Hs99999902_m1), and IGF1 (Hs01547656_m1) was measured relative to GAPDH (Hs99999905_m1) using the ΔΔCt method after confirmation of parallel PCR amplification efficiencies on a Real-Time PCR ABI Prism 7500. PCR reactions were carried out under the following conditions: Initial denaturation at 95ºC for 5 min followed by cycles of denaturation (95ºC for 15 sec), primer annealing (60ºC for 1 min) and transcript extension (50ºC for 2 min) for 45 cycles.
Western immunoblotting
Surgically resected tissues were snap-frozen in liquid nitrogen and protein extracts were 
Quantitative IGFBP-6 immunoassay
The levels of secreted IGFBP-6 in DD and PF cell conditioned media was assessed using Bio-Rad).
WST-1 cell proliferation assay
The WST-1 assay (Millipore/Chemicon, Billerica, MA) was adapted to measure changes in the proliferation of primary fibroblasts grown on type-1 collagen, the most abundant protein component of palmar fascia. We have included type-1 collagen substrates in all our assays to more closely replicate in vivo conditions. In brief, 2 shown). We interpret these outputs as net proliferation (total cell number changes due to the combined effects of mitogenesis and apoptosis). All experiments were performed at least three times on a minimum of 4 DD, PF and CT cell lines, each assessed in triplicate.
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Fibroblast populated collagen lattice assays
Collagen contraction assays were carried out using modified versions of Bell et al [26] and Tomasek et al [27] . In brief, the contractility of DD, PF and CT cells at low passage (≤ 6) were assessed in three-dimensional Fibroblast Populated Collagen Lattices (FPCLs). Collagen lattices were cast in 24-well tissue culture trays with each well containing 400 l collagen (final collagen concentration of 1.8 mg/ml), 100
l neutralization solution, treatment or vehicle, and 1 x 10 5 cells. FPCLs were maintained in MEM supplemented with 2% FBS and 1% antibiotic-antimycotic solution at 37 o C in 5% CO 2 . For "relaxed" FPCLs (rFPCLs), lattices were allowed to polymerize for 1 hr before being gently releasing from the sides and bottoms of the wells using a metal rod.
Relaxed FPCLs typically undergo gradual lattice contraction over 24 hrs in tissue culture media. Floating lattices for rFPCLs were digitally scanned at 24.0 hrs only. For "stressed" FPCLs (sFPCLs), the collagen lattices remained attached to the wells for 72 hrs to allow the cells to induce (and respond to) stress within the lattice and differentiate towards a contractile myofibroblast phenotype [28] . Lattices were released after 72 hrs, typically resulting in rapid contraction over 6 hrs. Floating lattices for sFPCLs were digitally scanned at release (0 hrs), 0.5 hrs, 1.0 hrs, 2.0 hrs and 6.0 hrs. The areas of individual lattices in rFPCL and sFPCLs were determined using the freehand tool in ImageJ software. Sequential area calculations were then normalized to the area of the lattice (i.e. the area of the well in which the lattice was cast) prior to release. All experiments were performed on a minimum of 3 and a maximum of 10 DD, PF and CT cell lines, each assessed in 3 separate experiments, in triplicate.
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Statistical analyses:
Statistical analysis was conducted using SPSS v. 17 and Microsoft Excel 2007 statistical software. For sFPCL data, repeated measures analysis of variance analyses were used to assess the significance of treatment effects and treatment/time interactions to distinguish overall treatment-induced changes in contractility from treatment-induced changes in contractility that became significant over time. Significant treatment/time interactions were further assessed with simple main effects analyses to determine at which time point a treatment had a significant effect. Paired t-tests were used to determine significant changes in contractility at 24 hours in rFPCLs and in proliferation by change score analysis between day 7 and day 1. Results were deemed significant when p<0.05.
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Results
IGFBP6 mRNA and IGFBP-6 levels are attenuated in Dupuytren's Disease tissues and in DD cells
While IGFBP6 has been identified as a significantly down-regulated gene transcript in gene array studies comparing DD tissues to phenotypically unaffected palmar fascia [19, 21] , corresponding changes in IGFBP-6 levels have not been reported. As shown in (Fig.1D ).
IGF2 mRNA and IGF-II levels are increased in DD cells
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As IGFBP-6 has been reported to elicit effects by sequestering IGF-II, we assessed basal IGF2 expression in DD and PF cells. IGF2 mRNA levels were consistently (n= 6 patients) and significantly (p<0.05) increased in DD cells relative to patient-matched PF cell controls and non patient-matched CT cells (Fig.2A) . In contrast to IGF2, the expression of IGF1, encoding insulin-like growth factor-I, was unchanged between DD and PF cells (Fig. 2B) . To determine if increased IGF2 expression resulted in increased IGF-II secretion, we assessed IGF-II levels in DD cord tissue and DD cells lysates. As shown in Fig.2C , IGF-II immunoreactivity was increased in DD tissue and cell lysates relative to normal palmar fascia tissue and PF cell lysates. Multiple bands correlating with precursor forms of IGF-II, including "big" IGF-II and variably glycosylated pro-IGF-II previously reported in human serum [29] were evident in all cell lysates. As our findings indicated reciprocal changes in IGFBP6 and IGF2 mRNA levels and IGFBP-6
and IGF-II protein levels in DD cells relative to controls, we compared the effects of recombinant IGFBP-6 and recombinant IGF-II, individually and in combination, on the net proliferation and contractility of DD and PF cells.
IGFBP-6 inhibits DD cell proliferation in an IGF-II independent manner
Based on our analyses of IGFBP-6 secretion by CT cells (Fig. 1D) and previous studies in tumor cells [30] , we chose to assess the effects of 400 ng/ml of recombinant IGFBP-6 on net cellular proliferation. As shown in Fig.3A , a single treatment with 400 ng/ml of recombinant IGFBP-6 on day 0 induced a significant reduction in DD (p<0.01), PF and CT (each p<0.05) cell proliferation over the subsequent 7 days relative to vehicle treated cells. While a single treatment with recombinant IGF-II at 100 ng/ml significantly
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enhanced CT cell proliferation over 7 days (p<0.05), no significant effects of IGF-II treatment on the proliferation of DD or PF cells were detected (Fig. 3B) .
As shown in proliferation than IGFBP-6, although both treatments had statistically significant negative effects relative to vehicle treated cells (p<0.01).
IGF-II enhances DD cell contraction of collagen lattices
To assess the effects of IGF-II and IGFBP-6 on DD and PF cell contractility, we utilized two types of fibroblast populated collagen lattice assays, relaxed FPCL (rFPCL) and stressed FPCLs (sFPCL) [28, [32] [33] [34] [21, 35, 36] . The 72 hr incubation period in the presence of treatments in the sFPCL protocol allowed us to distinguish the effects of treatment-induced myofibroblast differentiation [37] from the immediate effects of treatment that are measured in rFPCLs [33] .
DD cells were more contractile than PF cells in rFPCL assays in the absence of treatment (Fig. 4A) . IGFBP-6 (400 ng/ml) did not significantly affect the contractility of DD, PF or CT cells in rFPCLs (data not shown). IGF-II (100 ng/ml) significantly enhanced rFPCL contraction by DD cells (p<0.05) but did not significantly affect PF or
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CT cell contractility (Fig. 4A) . Platelet derived growth factor (PDGF), an established inducer of fibroblast contractility in rFPCLs [33] , enhanced both DD and PF cell contractility in these assays.
IGFBP-6 (400 ng/ml) did not significantly affect the contractility of DD, PF or CT cells in sFPCLs (data not shown). IGF-II treatment significantly enhanced both PF (p<0.05) and DD (p<0.001) cell contractility over the 6 hrs after lattice release (Fig. 4C and Fig. 4D respectively) . In addition to treatment effects, significant IGF-II treatment/time interactions were evident for both cell types (p<0.01). While IGF-II significantly induced DD cells contraction at all time points after release, the level of significance increased from p<0.01 at release to p<0.001 6 hrs after release. Significant effects of IGF-II treatment were only evident 2 hours after release in PF cells (p<0.05).
TGF-1 treatment (12.5 ng/ml) significantly enhanced DD cell (p<0.01) contractility in these assays, whereas a significant TGF-1 treatment/time interaction was evident in PF cells (p<0.01) at 6 hrs after lattice release (p<0.01) (Fig. 4B) . IGF-II did not significantly affect sFPCL contraction by CT cells (data not shown). Co-treatments with equimolar IGFBP-6 and IGF-II abrogated the IGF-II induced contractility of both DD and PF cells (Fig.5A ).
As TGF-1 signaling intermediates and IGF-II have been reported to elicit combinatorial effects on myofibroblast differentiation in murine fibroblasts [38] , we assessed the effects of treating PF and DD cells with both growth factors in combination (Fig.5B) . While TGF-1 and IGF-II treatments significantly enhanced the contractility of PF and DD cells relative to vehicle treated controls, no combinatorial treatment effects were detected over treatment with either factor in isolation.
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Discussion
In this study, we have identified IGFBP6 and IGF2 as reciprocally dysregulated genes in DD cells relative to PF cells. Previous studies have reported the increased TGF-1 expression and sensitivity, enhanced contractility,  smooth muscle actin (SMA) expression and myofibroblast differentiation in DD cells [39] [40] [41] , features shared with primary myofibroblast-like cells derived from other fibroses [42] [43] [44] . Other than TGF-, very few of the dysregulated genes in DD cells have been functionally linked to the main characteristics of DD development, namely fibroblast proliferation and palmar fascia contraction by myofibroblasts. Based on our findings, we hypothesize that down regulated IGFBP6 expression and up regulated IGF2 expression jointly contribute to DD progression by promoting fibroblast proliferation, contractility and palmar fascia contraction in DD (Fig.6 ).
As IGFBP-6 is a high affinity IGF-II binding protein [23] , we hypothesized that attenuation of IGFBP6 expression and IGFBP-6 protein levels in DD would enhance IGF-II availability and signaling. IGF-II signaling can promote mitogenesis [45] [46] [47] [48] and inhibit apoptosis [49, 50] , and IGFBP-6 can antagonize these effects by sequestering and inhibiting IGF-II signaling [30, [51] [52] [53] . However, co-treatment with equimolar IGFBP-6
and IGF-II elicited similar negative effects on the net proliferation compared to cells treated with IGFBP-6 alone. Consistent with these findings, an IGFBP-6 analog with attenuated IGF-II binding capacity (mIGFBP-6) exhibited similar effects on PF cell proliferation relative to native IGFBP-6. These data suggest that IGFBP-6 inhibits PF cell proliferation through mechanisms that are independent of IGF-II sequestration, consistent with a subset of reports of IGFBP-6 actions in other diseases [31, 54, 55] . In
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contrast to PF and CT cells, mIGFBP-6 was significantly less effective at inhibiting the DD cell proliferation than native IGFBP-6. IGF2 expression is enhanced in DD cells relative to PF and CT cells, and exogenous IGF-II treatment did not promote DD cell proliferation (Fig. 3B) . We speculate that increased endogenous IGF-II expression in DD may be one of (potentially several) factors that enhance DD cell survival (rather than proliferation) in a low IGFBP-6 environment. The identification and elucidation of the IGF-II dependent and independent mechanisms activated by IGFBP-6 in DD cells will be a focus of future studies.
In contrast to its inhibitory effects on cellular proliferation, IGFBP-6 treatment did not significantly inhibit cellular contractility. However, IGFBP-6 was effective at attenuating the increase in PF and DD cell contractility induced by IGF-II treatment (Fig.   5A ). Overall, our data imply two distinct consequences of IGFBP-6 depletion in DD that are likely to enhance disease progression; the attenuation of IGF-II dependent and/or independent processes that increase the net proliferation of palmar fascia cells, and the enhancement of IGF-II induced cellular contractility.
The increased TGF-1 expression and sensitivity and enhanced basal contractility of DD cells [39] [40] [41] suggests that DD cells have differentiated further toward a myofibroblast phenotype than PF cells. Our analyses of DD and PF cells treated with TGF-1 or IGF-II revealed some interesting, divergent behaviors in these genetically matched cells at differing stages of differentiation. TGF-1 treatment significantly enhanced DD cell contractility (p<0.01) but no significant treatment/time interactions were evident, suggesting that the pro-contractile effects of TGF-1 treatment were induced prior to, and not after, lattice release. In contrast, no significant TGF-1
treatment effects on PF cells were detected, and a significant (p<0.01) time/treatment interaction was evident, suggesting that most of the contractility induced by TGF-1 in PF cells occurred during the lattice contraction phase after release. These differences are visually evident in the parallel versus divergent contraction curves in Fig. 4C and process that typically requires a 48-72 hr pre-incubation period under isometric tension.
We speculate that IGF-II enhances the three-dimensional migration of DD cells in these rFPCLs, an effect previously shown for normal fibroblasts treated with PDGF [33] .
PDGF treatment significantly enhanced rFPCL contraction by both DD (p<0.01) and PF (p<0.05) cells (Fig. 4A) , whereas TGF-1, which significantly enhanced DD cell contraction in sFPCLs (Fig. 4B) Alternatively, novel therapies that restore IGFBP-6 levels to those evident in normal palmar fascia may be sufficient to attenuate IGF-II signaling and myofibroblast contractility.
Conclusion
These novel findings support our hypothesis that the attenuation of IGFBP6 expression and enhancement of IGF2 expression promote DD development. IGFBP-6
inhibited DD proliferation, while exogenous IGF-II potently enhanced the contractility of DD cells. Future studies will focus on elucidating the IGF-II-independent mechanisms regulated by IGFBP-6, and the mechanisms by which IGF-II signaling enhances DD cell contractility. These findings implicate IGFBP6 and IGF2 as novel regulators of DD cell proliferation and contractility that may have utility as targets to inhibit DD progression and recurrence.
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